Keapstone Therapeutics is focused on developing innovative small molecule activators that target the Nrf2-ARE pathway, which plays a crucial role in neuroprotection for conditions such as Parkinson's disease and amyotrophic lateral sclerosis (ALS). By preventing the interaction between KEAP1 and Nrf2, these compounds facilitate the translocation of Nrf2 into the nucleus, where it can activate various cellular defense mechanisms. This activation is essential for improving redox balance, enhancing mitochondrial function, promoting autophagy, and reducing inflammation. The unique aspect of this approach is its ability to simultaneously target multiple biological pathways associated with neurodegeneration through a single therapeutic agent.

The underlying science of Keapstone's technology is rooted in addressing the complexities of neurodegenerative diseases, which are influenced by a range of molecular events. Traditional therapies have often failed because they target individual pathways without considering the interconnected nature of these biological processes. By leveraging the KEAP1-Nrf2 pathway, Keapstone aims to overcome these challenges by promoting the activation of NRF2, a transcription factor that regulates a wide array of protective genes. This strategy not only addresses redox imbalance and mitochondrial dysfunction but also enhances autophagy and mitigates inflammation, positioning their therapies as a novel combination treatment approach for neurodegenerative disorders.

United Kingdom

Keapstone Therapeutics is a single asset biotech developing drugs that target the Nrf2 signalling pathway (KEAP1 inhibitors) for two devastating conditions – Parkinson’s and Motor Neuron Disease (MND) – which together affect more than 130,000 people in the UK. Keapstone was co-founded in February 2017 by the University of Sheffield, Parkinson’s UK and Dr Richard Mead and Prof Pamela Shaw of the Sheffield Institute for Translational Neuroscience (SITraN). The company combines world-leading research from the university with funding and expertise from Parkinson’s UK and consultants and discovery partners with extensive drug development expertise.

Keapstone Therapeutics

Company Details